Valuation: CSL Limited

Market Cap 39.94B 35.05B 32.64B 30.02B 56.27B 3,816B 57.24B 387B 152B 1,892B 150B 147B 6,538B P/E 2026 *
-44.3x
P/E 2027 * 27.8x
Enterprise Value 48.67B 42.71B 39.77B 36.58B 68.57B 4,649B 69.75B 472B 185B 2,306B 183B 179B 7,966B EV / Sales 2026 *
3.17x
EV / Sales 2027 * 3.08x
Free-Float
99.3%
Yield 2026 *
3.41%
Yield 2027 * 3.5%
1 day+7.15%
1 week+8.59%
Current month+11.62%
1 month+10.99%
3 months+1.82%
6 months-28.61%
Current year-25.82%
1 week 113.75
Extreme 113.75
128.75
1 month 113.69
Extreme 113.69
128.75
Current year 90
Extreme 90
184.62
1 year 90
Extreme 90
275.79
3 years 90
Extreme 90
313.55
5 years 90
Extreme 90
319.78
10 years 90
Extreme 90
342.75
Manager TitleAgeSince
Chief Executive Officer 63 2026-02-10
Director of Finance/CFO 52 2025-10-06
Chief Operating Officer - 2025-04-30
Director TitleAgeSince
Director/Board Member 72 2018-10-16
Director/Board Member 70 2011-02-01
Director/Board Member 71 2019-12-08
Date Insider Type Main position Quantity % Market Cap.
6/1/26 Buy

Director

1,036 0.0002%
5/26/26 Buy

Chief Executive Officer

1,100 0.0002%
5/26/26 Buy

Chief Executive Officer

1,100 0.0002%
Change 5-day change 1-year change 3-year change Capi.($)
+7.15%+8.59%-52.92%-52.31% 39.94B
+4.20%+2.96%+24.44%-6.82% 70.73B
+1.79%+2.58%+39.89%+213.85% 54.27B
+0.26%+54.90%+54.90%+54.90% 49.28B
+2.73%+1.21%+59.04%-22.48% 30.36B
+9.30%+10.68%+85.19%+105.94% 25.96B
+0.31%-6.46%+64.57%-52.97% 22.14B
-0.83%-3.25%-10.71%+157.95% 19.96B
+0.60%+0.39%+65.65%+126.60% 16.72B
+1.70%+3.76%+85.05%+148.55% 16.77B
Average +2.73%+2.40%+41.51%+67.32% 34.61B
Weighted average by Cap. +3.03%+3.22%+35.33%+58.92%

Financials

2026 *2027 *
Net sales 15.37B 13.49B 12.56B 11.56B 21.66B 1,469B 22.03B 149B 58.34B 728B 57.71B 56.47B 2,516B 15.58B 13.67B 12.73B 11.71B 21.95B 1,488B 22.32B 151B 59.11B 738B 58.48B 57.21B 2,550B
Net income -974M -855M -796M -732M -1.37B -93.07B -1.4B -9.44B -3.7B -46.16B -3.66B -3.58B -159B 1.19B 1.04B 970M 892M 1.67B 113B 1.7B 11.51B 4.5B 56.24B 4.46B 4.36B 194B
Net Debt 8.73B 7.66B 7.13B 6.56B 12.3B 834B 12.51B 84.61B 33.12B 413B 32.76B 32.05B 1,429B 7.99B 7.01B 6.53B 6.01B 11.26B 764B 11.45B 77.49B 30.33B 379B 30.01B 29.36B 1,308B
Logo CSL Limited
CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with approximately 325 plasma collection centers in the United States, Europe and China. The Company operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China (including Hong Kong). Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam, and others.
Employees
29,904
Date Price Change Volume
26-07-29 A$128.07 +7.15% 2,836,774
26-07-28 A$119.52 +2.69% 739,358
26-07-27 A$116.39 +1.90% 639,541
26-07-24 A$114.22 -1.32% 1,114,296
26-07-23 A$115.75 -1.86% 1,250,961
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
83.39USD
Average target price
96.97USD
Spread / Average Target
+16.28%

Quarterly revenue - Rate of surprise